Dr Richard Hoglund
Head of Pharmacometrics
Richard Hoglund heads the pharmacometrics group at the department of Clinical Pharmacology, MORU. He has a background in chemical engineering and pharmacology and his research is mainly focused on pharmacometrics, pharmacokinetics, pharmacodynamics and mathematical modelling in tropical medicine research, with a particular focus on antimalarial therapy.
More specific, his main research aims to optimise current and future antimalarial therapies by utilizing pharmacometric methodologies. A pharmacometric modelling approach can identify specific groups at risk of treatment failure and the derived pharmacometric models can help to evaluate and suggest new dose regimens to improve the treatment of malaria.
A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics.
Wattanakul T. et al, (2022), Expert Rev Clin Pharmacol
Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside
Assmus F. et al, (2022), PLOS Neglected Tropical Diseases, 16, e0010219 - e0010219
Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence".
Ding J. et al, (2021), Clinical pharmacology and therapeutics, 110, 24 - 25
Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa
Fanello C. et al, (2021), Antimicrobial Agents and Chemotherapy, 65
Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria
Wattanakul T. et al, (2021), Antimicrobial Agents and Chemotherapy, 65